Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases

This randomized phase II study aims to investigate whether the addition of bevacizumab to
standard corticosteroid therapy results in greater improvement in symptoms and less
treatment-induced symptoms compared with standard corticosteroid therapy for patients with
symptomatic brain radionecrosis following radiosurgery. It is hypothesized that the addition
of bevacizumab to standard care corticosteroids will reduce treatment-induced toxicities and
improve neurologic impairments in patients with brain radionecrosis following radiosurgery
for brain metastases.


bevacizumab, corticosteroids, placebo


Radionecrosis, Brain Metastases


Caroline Chung, MD

See list of participating sites